Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 8/2012

01-08-2012 | Review Article

Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs

Authors: Miroslav Dostalek, Fatemeh Akhlaghi, Dr Martina Puzanovova

Published in: Clinical Pharmacokinetics | Issue 8/2012

Login to get access

Abstract

The effects of diabetes mellitus on the pharmacokinetics and pharmacodynamics of drugs have been well described in experimental animal models; however, only minimal data exist for humans and the current knowledge regarding the effects of diabetes on these properties remains unclear. Nevertheless, it has been observed that the pharmacokinetics and pharmacodynamics of drugs are changed in subjects with diabetes. It has been reported that diabetes may affect the pharmacokinetics of various drugs by affecting (i) absorption, due to changes in subcutaneous adipose blood flow, muscle blood flow and gastric emptying; (ii) distribution, due to non-enzymatic glycation of albumin; (iii) biotransformation, due to regulation of enzymes/transporters involved in drug biotransformation; and (iv) excretion, due to nephropathy. Previously published data also suggest that diabetes-mediated changes in the pharmacokinetics of a particular drug cannot be translated to others.
Although clinical studies exploring the effect of diabetes on pharmacodynamics are still very limited, there is evidence that disease-mediated effects are not limited only to pharmacokinetics but also alter pharmacodynamics. However, for many drugs it remains unclear whether these influences reflect diabetes-mediated changes in pharmacokinetics rather than pharmacodynamics. In addition, even though diabetes-mediated pharmacokinetics and pharmacodynamics might be anticipated, it is important to study the effect on each drug and not generalize from observed data.
The available data indicate that there is a significant variability in drug response in diabetic subjects. The discrepancies between individual clinical studies as well as between ex vivo and clinical studies are probably due to (i) the restricted and focused population of subjects in clinical studies; (ii) failure to consider type, severity and duration of the disease; (iii) histopathological characteristics generally being missing; and (iv) other factors such as varying medication use, dietary protein intake, age, sex and obesity. The obesity epidemic in the developed world has also inadvertently influenced the directions of pharmacological research.
This review attempts to map new information gained since Gwilt published his paper in Clinical Pharmacokinetics in 1991. Although a large body of research has been conducted and significant progress has been made, we still have to conclude that the available information regarding the effect of diabetes on pharmacokinetics and pharmacodynamics remains unclear and further clinical studies are required before we can understand the clinical significance of the effect. An understanding of diabetes-mediated changes as well as of the source of the variability should lead to the improvement of the medical management and clinical outcomes in patients with this widespread disease.
Literature
1.
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 May; 27(5): 1047–53PubMedCrossRef
2.
International Diabetes Federation Task Force on Diabetes Health Economy. Diabetes heath economics: facts, figures, and forecasts. Brussels: International Diabetes Federation, 1997
3.
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 Sep; 21(9): 1414–31PubMedCrossRef
4.
Rossing P, de Zeeuw D. Need for better diabetes treatment for improved renal outcome. Kidney Int Suppl 2011 Mar; (120): S28–32CrossRef
5.
King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults: WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 1993 Jan; 16(1): 157–77PubMedCrossRef
6.
Arslanian S. Type 2 diabetes in children: clinical aspects and risk factors. Horm Res 2002; 57 Suppl. 1: 19–28PubMed
7.
8.
9.
Herder C, Karakas M, Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther 2011 Jul; 90(1): 52–66PubMedCrossRef
10.
Wing RR, Goldstein MG, Acton KJ, et al. Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care 2001 Jan; 24(1): 117–23PubMedCrossRef
11.
Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005 Sep; 99(3): 1193–204PubMedCrossRef
12.
LaMonte MJ, Blair SN, Church TS. Physical activity and diabetes prevention. J Appl Physiol 2005 Sep; 99(3): 1205–13PubMedCrossRef
13.
Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004 Jun 1; 140(11): 945–50PubMedCrossRef
14.
Rendell M, Lassek WD, Ross DA, et al. A pharmaceutical profile of diabetic patients. J Chronic Dis 1983; 36(2): 193–202PubMedCrossRef
15.
Isacson D, Stalhammar J. Prescription drug use among diabetics: a population study. J Chronic Dis 1987; 40(7): 651–60PubMedCrossRef
16.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2007 [published erratum appears in Diabetes Care 2008; 31 (6): 1271]. Diabetes Care 2008; 31(3): 596–615CrossRef
17.
18.
Aggarwal S. What’s fueling the biotech engine-2010 to 2011. Nat Biotechnol 2011; 29(12): 1083–9PubMedCrossRef
19.
Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991 Jun; 20(6): 477–90PubMedCrossRef
20.
Cashion AK, Holmes SL, Hathaway DK, et al. Gastroparesis following kidney/pancreas transplant. Clin Transplant 2004 Jun; 18(3): 306–11PubMedCrossRef
21.
Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels: implications for drug dosage regimens (part I). Clin Pharmacokinet 1990 Aug; 19(2): 147–59PubMedCrossRef
22.
Okabe N, Hashizume N. Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol Pharm Bull 1994 Jan; 17(1): 16–21PubMedCrossRef
23.
Wang T, Shankar K, Ronis MJ, et al. Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes. Crit Rev Toxicol 2007 Jun; 37(5): 413–59PubMedCrossRef
24.
Zhu L. Gastric mucosal blood flow and blood viscosity in patients with diabetes [in Chinese]. Zhonghua Yi Xue Za Zhi 1993 Aug; 73(8): 476–8, 511PubMed
25.
Jacobson ED, Chang AC. Comparison of gastrin and histamine on gastric mucosal blood flow. Proc Soc Exp Biol Med 1969 Feb; 130(2): 484–6PubMedCrossRef
26.
Jacobson ED, Linford RH, Grossman MI. Gastric secretion in relation to mucosal blood flow studied by a clearance technic. J Clin Invest 1966 Jan; 45(1): 1–13PubMedPubMedCentralCrossRef
27.
Moody FG. Oxygen consumption during thiocyanate inhibition of gastric acid secretion in dogs. Am J Physiol 1968 Jul; 215(1): 127–31PubMed
28.
Hasler WL, Coleski R, Chey WD, et al. Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. Am J Physiol Gastrointest Liver Physiol 2008 Jun; 294(6): G1 384–91CrossRef
29.
30.
Samsom M, Bharucha A, Gerich JE, et al. Diabetes mellitus and gastric emptying: questions and issues in clinical practice. Diabetes Metab Res Rev 2009 Sep; 25(6): 502–14PubMedCrossRef
31.
Domstad PA, Kim EE, Coupal JJ, et al. Biologic gastric emptying time in diabetic patients, using Tc-99m-labeled resin-oatmeal with and without metoclopramide. J Nucl Med 1980 Nov; 21(11): 1098–100PubMed
32.
Horowitz M, McNeil JD, Maddern GJ, et al. Abnormalities of gastric and esophageal emptying in polymyositis and dermatomyositis. Gastroenterology 1986 Feb; 90(2): 434–9PubMedCrossRef
33.
Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus. Am J Gastroenterol 1987 Jan; 82(1): 29–35PubMed
34.
Gilbey SG, Watkins PJ. Measurement by epigastric impedance of gastric emptying in diabetic autonomic neuropathy. Diabet Med 1987 Mar–Apr; 4(2): 122–6PubMedCrossRef
35.
Caballero-Plasencia AM, Muros-Navarro MC, Martin-Ruiz JL, et al. Gastroparesis of digestible and indigestible solids in patients with insulin-dependent diabetes mellitus or functional dyspepsia. Dig Dis Sci 1994 Jul; 39(7): 1409–15PubMedCrossRef
36.
Ziegler D, Schadewaldt P, Pour Mirza A, et al. [13C]octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia 1996 Jul; 39(7): 823–30PubMedCrossRef
37.
Lipp RW, Schnedl WJ, Hammer HF, et al. Evidence of accelerated gastric emptying in longstanding diabetic patients after ingestion of a semisolid meal. J Nucl Med 1997 May; 38(5): 814–8PubMed
38.
Dutta U, Padhy AK, Ahuja V, et al. Double blind controlled trial of effect of cisapride on gastric emptying in diabetics. Trop Gastroenterol 1999 Jul–Sep; 20(3): 116–9PubMed
39.
Loo FD, Palmer DW, Soergel KH, et al. Gastric emptying in patients with diabetes mellitus. Gastroenterology 1984 Mar; 86(3): 485–94PubMed
40.
Merio R, Festa A, Bergmann H, et al. Slow gastric emptying in type I diabetes: relation to autonomic and peripheral neuropathy, blood glucose, and glycemic control. Diabetes Care 1997 Mar; 20(3): 419–23PubMedCrossRef
41.
De Block CE, De Leeuw IH, Pelckmans PA, et al. Delayed gastric emptying and gastric autoimmunity in type 1 diabetes. Diabetes Care 2002 May; 25(5): 912–7PubMedCrossRef
42.
Meier M, Linke R, Tatsch K, et al. An advanced approach for the assessment of gastric motor function in long-term type 1 diabetes mellitus with and without autonomic neuropathy. Clin Auton Res 2002 Jun; 12(3): 197–202PubMedCrossRef
43.
Iber F, Parveen S, Vandrunen M, et al. Relation of symptoms to impaired stomach, small bowel, and colon motility in long-standing diabetes. Dig Dis Sci 1993; 38(1): 45–50PubMedCrossRef
44.
Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989 Mar; 32(3): 151–9PubMedCrossRef
45.
Wegener M, Borsch G, Schaffstein J, et al. Gastrointestinal transit disorders in patients with insulin-treated diabetes mellitus. Dig Dis 1990; 8(1): 23–36PubMedCrossRef
46.
Cotroneo P, Grattagliano A, Rapaccini GL, et al. Gastric emptying rate and hormonal response in type II diabetics. Diabetes Res 1991 Jun; 17(2): 99–104PubMed
47.
Annese V, Bassotti G, Caruso N, et al. Gastrointestinal motor dysfunction, symptoms, and neuropathy in noninsulin-dependent (type 2) diabetes mellitus. J Clin Gastroenterol 1999 Sep; 29(2): 171–7PubMedCrossRef
48.
Chang CS, Kao CH, Wang YS, et al. Discrepant pattern of solid and liquid gastric emptying in Chinese patients with type II diabetes mellitus. Nucl Med Commun 1996 Jan; 17(1): 60–5PubMedCrossRef
49.
Qi HB, Luo JY, Zhu YL, et al. Gastric myoelectrical activity and gastric emptying in diabetic patients with dyspeptic symptoms. World J Gastroenterol 2002 Feb; 8(1): 180–2PubMedPubMedCentralCrossRef
50.
51.
Boas I. Diseases of stomach. Leipzig: Georg Thieme, 1925
52.
Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 1994 Jun; 37(6): 543–51PubMedCrossRef
53.
Horowitz M, Wishart JM, Jones KL, et al. Gastric emptying in diabetes: an overview. Diabet Med 1996 Sep; 13 (9 Suppl. 5): S16–22PubMed
54.
Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001 Jul; 24(7): 1264–9PubMedCrossRef
55.
Kong MF, Horowitz M. Gastric emptying in diabetes mellitus: relationship to blood-glucose control. Clin Geriatr Med 1999 May; 15(2): 321–38PubMed
56.
Chang J, Rayner C, Jones K, et al. Diabetic gastroparesis: backwards and forwards. J Gastroenterol Hepatol 2011; 26 Suppl. 1: 46–57PubMedCrossRef
57.
Horowitz M, O’Donovan D, Jones KL, et al. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002 Mar; 19(3): 177–94PubMedCrossRef
58.
Naesens M, Verbeke K, Vanrenterghem Y, et al. Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. Br J Clin Pharmacol 2007 May; 63(5): 541–7PubMedCrossRef
59.
Bian RW, Lou QL, Gu LB, et al. Delayed gastric emptying is related to cardiovascular autonomic neuropathy in Chinese patients with type 2 diabetes. Acta Gastroenterol Belg 2011 Mar; 74(1): 28–33PubMed
60.
Lyrenas EB, Olsson EH, Arvidsson UC, et al. Prevalence and determinants of solid and liquid gastric emptying in unstable type I diabetes: relationship to postprandial blood glucose concentrations. Diabetes Care 1997 Mar; 20(3): 413–8PubMedCrossRef
61.
Wright RA, Clemente R, Wathen R. Diabetic gastroparesis: an abnormality of gastric emptying of solids. Am J Med Sci 1985 Jun; 289(6): 240–2PubMedCrossRef
62.
Troncon LE, Rosa-e-Silva L, Oliveira RB, et al. Abnormal intragastric distribution of a liquid nutrient meal in patients with diabetes mellitus. Dig Dis Sci 1998 Jul; 43(7): 1421–9PubMedCrossRef
63.
Horowitz M, Maddox AF, Wishart JM, et al. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991; 18(4): 229–34PubMedCrossRef
64.
Nowak TV, Johnson CP, Kalbfleisch JH, et al. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut 1995 Jul; 37(1): 23–9PubMedPubMedCentralCrossRef
65.
Kong MF, King P, Macdonald IA, et al. Euglycaemic hyperinsulinaemia does not affect gastric emptying in type I and type II diabetes mellitus. Diabetologia 1999 Mar; 42(3): 365–72PubMedCrossRef
66.
Frank JW, Saslow SB, Camilleri M, et al. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995 Sep; 109(3): 755–65PubMedCrossRef
67.
Schwartz JG, Green GM, Guan D, et al. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 1996 May; 19(5): 468–71PubMedCrossRef
68.
Rayner CK, Samsom M, Jones KL, et al. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001 Feb; 24(2): 371–81PubMedCrossRef
69.
MacGregor IL, Gueller R, Watts HD, et al. The effect of acute hyperglycemia on gastric emptying in man. Gastroenterology 1976 Feb; 70(2): 190–6PubMed
70.
Russo A, Stevens JE, Chen R, et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab 2005 Aug; 90(8): 4489–95PubMedCrossRef
71.
Asmar M. New physiological effects of the incretin hormones GLP-1 and GIP. Dan Med Bull 2011 Feb; 58(2): B4248PubMed
72.
Drucker DJ, Nauck MA. The incretin system: glucagon-like pep tide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 Nov 11; 368(9548): 1696–705PubMedCrossRef
73.
Hillman M, Eriksson L, Mared L, et al. Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. J Cyst Fibros 2012 Mar; 11(2): 144–9PubMedCrossRef
74.
Kuo P, Stevens JE, Russo A, et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis: effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011 May; 96(5): E851–5PubMedCrossRef
75.
Triantafyllou K, Kalantzis C, Papadopoulos AA, et al. Video-capsule endoscopy gastric and small bowel transit time and completeness of the examination in patients with diabetes mellitus. Dig Liver Dis 2007 Jun; 39(6): 575–80PubMedCrossRef
76.
Jung HK, Kim DY, Moon IH, et al. Colonic transit time in diabetic patients: comparison with healthy subjects and the effect of autonomic neuropathy. Yonsei Med J 2003 Apr 30; 44(2): 265–72PubMedCrossRef
77.
Wu MJ, Chang CS, Cheng CH, et al. Colonic transit time in long-term dialysis patients. Am J Kidney Dis 2004 Aug; 44(2): 322–7PubMedCrossRef
78.
Iida M, Ikeda M, Kishimoto M, et al. Evaluation of gut motility in type II diabetes by the radiopaque marker method. J Gastroenterol Hepatol 2000 Apr; 15(4): 381–5PubMedCrossRef
79.
Werth B, Meyer-Wyss B, Spinas GA, et al. Non-invasive assessment of gastrointestinal motility disorders in diabetic patients with and without cardiovascular signs of autonomic neuropathy. Gut 1992 Sep; 33(9): 1199–203PubMedPubMedCentralCrossRef
80.
81.
Dooley CP, el Newihi HM, Zeidler A, et al. Abnormalities of the migrating motor complex in diabetics with autonomic neuropathy and diarrhea. Scand J Gastroenterol 1988 Mar; 23(2): 217–23PubMedCrossRef
82.
Oliveira RB, Troncon LE, Meneghelli UG, et al. Gastric accommodation to distension and early gastric emptying in diabetics with neuropathy. Braz J Med Biol Res 1984; 17(1): 49–53PubMed
83.
Fraser RJ, Horowitz M, Maddox AF, et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990 Nov; 33(11): 675–80PubMedCrossRef
84.
Jebbink RJ, Samsom M, Bruijs PP, et al. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type I diabetes mellitus. Gastroenterology 1994 Nov; 107(5): 1390–7PubMedCrossRef
85.
Della-Coletta A, Eller M. The bioavailability of tolazamid in diabetic patients and healthy subjects [abstract no. PP 1301]. Pharmacol Res 1988; 5: S174
86.
Adithan C, Danda D, Shashindran CH, et al. Differential effect of type I and type II diabetes mellitus on antipyrine elimination. Methods Find Exp Clin Pharmacol 1989 Dec; 11(12): 755–8PubMed
87.
O’Connell ME, Awni WM, Goodman M, et al. Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis. J Clin Pharmacol 1987 Aug; 27(8): 610–4PubMedCrossRef
88.
Wahlin-Boll E, Almer LO, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin Pharmacokinet 1982 Jul–Aug; 7(4): 363–72PubMedCrossRef
89.
Fuccella LM, Tamassia V, Valzelli G. Metabolism and kinetics of the hypoglycemic agent glipizide in man: comparison with glibenclamide. J Clin Pharmacol New Drugs 1973 Feb–Mar; 13(2): 68–75PubMedCrossRef
90.
Stacher G, Lenglinger J, Bergmann H, et al. Gastric emptying: a contributory factor in gastro-oesophageal reflux activity? Gut 2000 Nov; 47(5): 661–6PubMedPubMedCentralCrossRef
91.
Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003 Feb; 98(2): 259–63PubMed
92.
Havelund T, Oster-Jorgensen E, Eshoj O, et al. Effects of cisapride on gastroparesis in patients with insulin-dependent diabetes mellitus: a double-blind controlled trial. Acta Med Scand 1987; 222(4): 339–43PubMedCrossRef
93.
de Caestecker JS, Ewing DJ, Tothill P, et al. Evaluation of oral cisapride and metoclopramide in diabetic autonomic neuropathy: an eight-week double-blind crossover study. Aliment Pharmacol Ther 1989 Feb; 3(1): 69–81PubMedCrossRef
94.
Camilleri M, Malagelada JR, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989 Mar; 96(3): 704–12PubMedCrossRef
95.
Nosadini R, De Kreutzenberg S, Duner E, et al. Porcine and human insulin absorption from subcutaneous tissues in normal and insulin-dependent diabetic subjects: a deconvolution-based approach. J Clin Endocrinol Metab 1988; 67(3): 551–9PubMedCrossRef
96.
Moore EW, Mitchell ML, Chalmers TC. Variability in absorption of insulin-I 131 in normal and diabetic subjects after subcutaneous and intramuscular injection. J Clin Invest 1959 Jul; 38(7): 1222–7PubMedPubMedCentralCrossRef
97.
Leinonen H, Matikainen E, Juntunen J. Permeability and morphology of skeletal muscle capillaries in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982 Mar; 22(3): 158–62PubMedCrossRef
98.
Weinstein L, Meade RH. Absorption and excretion of penicillin injected into the muscles of patients with diabetes mellitus. Nature 1961 Dec 9; 192: 987–8PubMedCrossRef
99.
Hildebrandt P, Sestoft L, Nielsen SL. The absorption of subcutaneously injected short-acting soluble insulin: influence of injection technique and concentration. Diabetes Care 1983 Sep–Oct; 6(5): 459–62PubMedCrossRef
100.
Sestoft L, Volund A, Gammeltoft S, et al. The biological properties of human insulin: subcutaneous absorption, receptor binding and the clinical effect in diabetics assessed by a new statistical method. Acta Med Scand 1982; 212(1–2): 21–8PubMed
101.
Kolendorf K, Bojsen J, Nielsen SL. Adipose tissue blood flow and insulin disappearance from subcutaneous tissue. Clin Pharmacol Ther 1979 May; 25 (5 Pt 1): 598–604PubMedCrossRef
102.
Lauritzen T, Binder C, Faber OK. Importance of insulin absorption, subcutaneous blood flow, and residual beta-cell function in insulin therapy. Acta Paediatr Scand Suppl 1980; 283: 81–5PubMedCrossRef
103.
Haggendal E, Steen B, Svanborg A. Blood flow in subcutaneous fat tissue in patients with diabetes mellitus. Acta Med Scand 1970 Jan–Feb; 187(1–2): 49–53PubMed
104.
Dimitriadis G, Lambadiari V, Mitrou P, et al. Impaired postprandial blood flow in adipose tissue may be an early marker of insulin resistance in type 2 diabetes. Diabetes Care 2007 Dec; 30(12): 3128–30PubMedCrossRef
105.
Coppack SW, Evans RD, Fisher RM, et al. Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism 1992 Mar; 41(3): 264–72PubMedCrossRef
106.
Blaak EE, van Baak MA, Kemerink GJ, et al. Beta-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects. Metabolism 1995 Feb; 44(2): 183–7PubMedCrossRef
107.
Summers LK, Samra JS, Humphreys SM, et al. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 1996 Dec; 91(6): 679–83CrossRef
108.
Jansson PA, Larsson A, Lonnroth PN. Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998 Oct; 28(10): 813–8PubMedCrossRef
109.
Karpe F, Fielding BA, Ilic V, et al. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 2002 Aug; 51(8): 2467–73PubMedCrossRef
110.
Regensteiner JG, Popylisen S, Bauer TA, et al. Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med 2003; 8(3): 169–75PubMedCrossRef
111.
Kingwell BA, Formosa M, Muhlmann M, et al. Type 2 diabetic individuals have impaired leg blood flow responses to exercise: role of endothelium-dependent vasodilation. Diabetes Care 2003 Mar; 26(3): 899–904PubMedCrossRef
112.
McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992 Aug; 35(8): 771–6PubMed
113.
Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996 Mar 1; 27(3): 567–74PubMedCrossRef
114.
Schneider JG, Tilly N, Hierl T, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens 2002 Nov; 15(11): 967–72PubMedCrossRef
115.
Marin P, Andersson B, Krotkiewski M, et al. Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care 1994 May; 17(5): 382–6PubMedCrossRef
116.
Mathieu-Costello O, Kong A, Ciaraldi TP, et al. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism 2003 May; 52(5): 540–6PubMedCrossRef
117.
Ritov VB, Menshikova EV, He J, et al. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005 Jan; 54(1): 8–14PubMedCrossRef
118.
Kelley DE, He J, Menshikova EV, et al. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002 Oct; 51(10): 2944–50PubMedCrossRef
119.
Yee GC, Evans WE. Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides. Pharmacotherapy 1981 Jul–Aug; 1(1): 55–75PubMedCrossRef
120.
Lerner PI, Weinstein L. Abnormalities of absorption of benzylpenicillin G and sulfisoxazole in patients with diabetes mellitus. Am J Med Sci 1964 Jul; 248:37–51PubMedCrossRef
121.
Bonadonna RC, Groop L, Kraemer N, et al. Obesity and insulin resistance in humans: a dose-response study. Metabolism 1990 May; 39(5): 452–9PubMedCrossRef
122.
Rexrode KM, Manson JE, Hennekens CH. Obesity and cardiovascular disease. Curr Opin Cardiol 1996 Sep; 11(5): 490–5PubMedCrossRef
123.
Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49(2): 71–87PubMedCrossRef
124.
Benedek IH, Fiske 3rd WD, Griffen WO, et al. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 1983 Dec; 16(6): 751–4PubMedPubMedCentralCrossRef
125.
Abernethy DR, Greenblatt DJ. Drug disposition in obese humans: an update. Clin Pharmacokinet 1986 May–Jun; 11(3): 199–213PubMedCrossRef
126.
Abernethy DR, Greenblatt DJ, Divoll M, et al. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983 Jun; 101(6): 873–80PubMed
127.
128.
Cohen MP, Ziyadeh FN, Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med 2006 May; 147(5): 211–9PubMedPubMedCentralCrossRef
129.
Day JF, Thorpe SR, Baynes JW. Nonenzymatically glucosylated albumin: in vitro preparation and isolation from normal human serum. J Biol Chem 1979 Feb 10; 254(3): 595–7PubMed
130.
Adithan C, Danda D, Swaminathan RP, et al. Effect of diabetes mellitus on salivary paracetamol elimination. Clin Exp Pharmacol Physiol 1988 Jun; 15(6): 465–71PubMedCrossRef
131.
Daintith H, Stevenson IH, O’Malley K. Influence of diabetes mellitus on drug metabolism in man. Int J Clin Pharmacol Biopharm 1976 Jan; 13(1): 55–8PubMed
132.
Salmela PI, Sotaniemi EA, Pelkonen RO. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus. Diabetes 1980 Oct; 29(10): 788–94PubMedCrossRef
133.
Murali KV, Adithan C, Shashindran CH, et al. Antipyrine metabolism in patients with diabetes mellitus. Clin Exp Pharmacol Physiol 1983 Jan–Feb; 10(1): 7–13PubMedCrossRef
134.
135.
Narang AP, Dutta DV, Khare AK. Impairment of drug clearance in patients with diabetes mellitus & liver cirrhosis. Indian J Med Res 1987 Mar; 85: 321–5PubMed
136.
Zysset T, Wietholtz H. Differential effect of type I and type II diabetes on antipyrine disposition in man. Eur J Clin Pharmacol 1988; 34(4): 369–75PubMedCrossRef
137.
Ruiz-Cabello F, Erill S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 1984 Nov; 36(5): 691–5PubMedCrossRef
138.
Worner W, Preissner A, Rietbrock N. Drug-protein binding kinetics in patients with type I diabetes. Eur J Clin Pharmacol 1992; 43(1): 97–100PubMedCrossRef
139.
Kearns GL, Kemp SF, Turley CP, et al. Protein binding of phenytoin and lidocaine in pediatric patients with type I diabetes mellitus. Dev Pharmacol Ther 1988; 11(1): 14–23PubMed
140.
Kemp SF, Kearns GL, Turley CP. Alteration of phenytoin binding by glycosylation of albumin in IDDM. Diabetes 1987 Apr; 36(4): 505–9PubMedCrossRef
141.
Trovik TS, Jaeger R, Jorde R, et al. Plasma protein binding of catecholamines, prazosin and propranolol in diabetes mellitus. Eur J Clin Pharmacol 1992; 43(3): 265–8PubMedCrossRef
142.
Trovik TS, Jaeger R, Jorde R, et al. Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness. Br J Clin Pharmacol 1994 Nov; 38(5): 427–32PubMedPubMedCentralCrossRef
143.
Reidenberg MM, Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984 Jan; 9 Suppl. 1: 18–26PubMedCrossRef
144.
Keller F, Maiga M, Neumayer HH, et al. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet 1984 Jul–Sep; 9(3): 275–82PubMedCrossRef
145.
Gatti G, Crema F, Attardo-Parrinello G, et al. Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther Drug Monit 1987 Dec; 9(4): 389–91PubMedCrossRef
146.
McNamara PJ, Blouin RA, Brazzell RK. The protein binding of phenytoin, propranolol, diazepam, and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res 1988 May; 5(5): 261–5PubMedCrossRef
147.
Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (part II). Clin Pharmacokinet 1990 Sep; 19(3): 218–29PubMedCrossRef
148.
Chase HP, Glasgow AM. Juvenile diabetes mellitus and serum lipids and lipoprotein levels. Am J Dis Child 1976 Oct; 130(10): 1113–7PubMed
149.
Fraze E, Donner CC, Swislocki AL, et al. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab 1985 Nov; 61(5): 807–11PubMedCrossRef
150.
Grainger-Rousseau T, McElnay J, Collier P. The influence of disease on plasma protein binding of drugs. Int J Pharmacol 1989; 54: 1–13CrossRef
151.
O’Byrne S, Barry MG, Collins WC, et al. Plasma protein binding of lidocaine and warfarin in insulin-dependent and non-insulin-dependent diabetes mellitus. Clin Pharmacokinet 1993 Feb; 24(2): 183–6PubMedCrossRef
152.
Stafford WL. Abnormality in the binding of an organic anion by diabetic serum. Lancet 1962 Feb 3; 1(7223): 243–5PubMedCrossRef
153.
154.
Ijaz S, Yang W, Winslet MC, et al. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003 Dec; 10(6): 447–56PubMedCrossRef
155.
Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999 Jan; 37(1): 8–19PubMed
156.
Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clin Pharmacokinet 1982 Mar–Apr; 7(2): 108–24PubMedCrossRef
157.
Petrides AS, Vogt C, Schulze-Berge D, et al. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994 Mar; 19(3): 616–27PubMedCrossRef
158.
Katbamma B, Petrelli M, McCullough A. The liver in diabetes mellitus and hyperlipidemia. In: Gitlin N, editor. The liver and the systemic disease. New York: Churchill Livingstone, 1997: 73–113
159.
Wang T, Fontenot RD, Soni MG, et al. Enhanced hepatotoxicity and toxic outcome of thioacetamide in streptozotocin-induced diabetic rats. Toxicol Appl Pharmacol 2000 Jul 15; 166(2): 92–100PubMedCrossRef
160.
Watkins 3rd JB, Sherman SE. Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin. J Pharmacol Exp Ther 1992 Mar; 260(3): 1337–43PubMed
161.
Shankar K, Vaidya VS, Apte UM, et al. Type 1 diabetic mice are protected from acetaminophen hepatotoxicity. Toxicol Sci 2003 Jun; 73(2): 220–34PubMedCrossRef
162.
Lee JH, Yang SH, Oh JM, et al. Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozotocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol 2010; 62(1): 1–23PubMedCrossRef
163.
Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2001 Jun; 2(2): 165–83PubMedCrossRef
164.
Sotaniemi EA, Pelkonen O, Arranto AJ, et al. Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 2002 Mar; 90(3): 155–60PubMedCrossRef
165.
Lucas D, Farez C, Bardou LG, et al. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 1998; 12(5): 553–8PubMedCrossRef
166.
Wang Z, Hall SD, Maya JF, et al. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003 Jan; 55(1): 77–85PubMedPubMedCentralCrossRef
167.
Hannon-Fletcher MP, O’Kane MJ, Moles KW, et al. Lymphocyte cytochrome P450-CYP2E1 expression in human IDDM subjects. Food Chem Toxicol 2001 Feb; 39(2): 125–32PubMedCrossRef
168.
Haufroid V, Ligocka D, Buysschaert M, et al. Cytochrome P4502E1 (CYP2E1) expression in peripheral blood lymphocytes: evaluation in hepatitis C and diabetes. Eur J Clin Pharmacol 2003 May; 59(1): 29–33PubMedCrossRef
169.
Song BJ, Veech RL, Saenger P. Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. J Clin Endocrinol Metab 1990 Oct; 71(4): 1036–40PubMedCrossRef
170.
Pucci L, Chirulli V, Marini S, et al. Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals. Pharmacol Res 2005 Jun; 51(6): 561–5PubMedCrossRef
171.
Adithan C, Sriram G, Swaminathan RP, et al. Effect of type II diabetes mellitus on theophylline elimination. Int J Clin Pharmacol Ther Toxicol 1989 May; 27(5): 258–60PubMed
172.
Zysset T, Wietholtz H. Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus. Eur J Clin Pharmacol 1991; 41(5): 449–52PubMedCrossRef
173.
Matzke GR, Frye RF, Early JJ, et al. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 2000 Feb; 20(2): 182–90PubMedCrossRef
174.
Korrapati MR, Vestal RE, Loi CM. Theophylline metabolism in healthy nonsmokers and in patients with insulin-dependent diabetes mellitus. Clin Pharmacol Ther 1995 Apr; 57(4): 413–8PubMedCrossRef
175.
Ueda H, Sakurai T, Ota M, et al. Disappearance rate of tolbutamide in normal subjects and in diabetes mellitus, liver cirrhosis, and renal disease. Diabetes 1963 Sep–Oct; 12: 414–9PubMedCrossRef
176.
Dyer JR, Davis TM, Giele C, et al. The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly. Br J Clin Pharmacol 1994 Sep; 38(3): 205–12PubMedPubMedCentralCrossRef
177.
Dostalek M, Court MH, Yan B, et al. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 2011 Jul; 163(5): 937–47PubMedPubMedCentralCrossRef
178.
Marques MP, Coelho EB, Dos Santos NA, et al. Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol 2002 Dec; 58(9): 607–14PubMedCrossRef
179.
Moises EC, Duarte Lde B, Cavalli Rde C, et al. Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. Eur J Clin Pharmacol 2008 Dec; 64(12): 1189–96PubMedCrossRef
180.
McRobie DJ, Glover DD, Tracy TS. Effects of gestational and overt diabetes on human placental cytochromes P450 and glutathione S-transferase. Drug Metab Dispos 1998 Apr; 26(4): 367–71PubMed
181.
McRobie DJ, Korzekwa KR, Glover DD, et al. The effects of diabetes on placental aromatase activity. J Steroid Biochem Mol Biol 1997 Sep–Oct; 63(1–3): 147–53PubMedCrossRef
182.
Juan D, Molitch ME, Johnson MK, et al. Unaltered drug metabolizing enzyme systems in type II diabetes mellitus before and during glyburide therapy. J Clin Pharmacol 1990 Oct; 30(10): 943–7PubMedCrossRef
183.
184.
Atalay M, Laaksonen DE, Niskanen L, et al. Altered antioxidant enzyme defences in insulin-dependent diabetic men with increased resting and exercise-induced oxidative stress. Acta Physiol Scand 1997 Oct; 161(2): 195–201PubMedCrossRef
185.
Dincer Y, Alademir Z, Ilkova H, et al. Susceptibility of glutatione and glutathione-related antioxidant activity to hydrogen peroxide in patients with type 2 diabetes: effect of glycemic control. Clin Biochem 2002 Jun; 35(4): 297–301PubMedCrossRef
186.
Graber R, Farine JC, Fumagalli I, et al. Apoptosis and oxidative status in peripheral blood mononuclear cells of diabetic patients. Apoptosis 1999 Aug; 4(4): 263–70PubMedCrossRef
187.
Sailaja YR, Baskar R, Saralakumari D. The antioxidant status during maturation of reticulocytes to erythrocytes in type 2 diabetics. Free Radic Biol Med 2003 Jul 15; 35(2): 133–9PubMedCrossRef
188.
Albrecht C, Simon-Vermot I, Elliott JI, et al. Leukocyte ABCA1 gene expression is associated with fasting glucose concentration in normoglycemic men. Metabolism 2004 Jan; 53(1): 17–21PubMedCrossRef
189.
Zhou H, Tan KC, Shiu SW, et al. Determinants of leukocyte adenosine triphosphate-binding cassette transporter G1 gene expression in type 2 diabetes mellitus. Metabolism 2008 Aug; 57(8): 1135–40PubMedCrossRef
190.
Mauldin JP, Nagelin MH, Wojcik AJ, et al. Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus. Circulation 2008 May 27; 117(21): 2785–92PubMedPubMedCentralCrossRef
191.
Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999 Jan; 88(1): 1–7PubMedCrossRef
192.
Suzuki Y, Arakawa M. The treatment of the uraemic diabetic. Are we doing enough? A view from Japan. Fumitake Gejyo and Collaborate Study Group. Nephrol Dial Transplant 1995; 10 Suppl. 7: 47–55PubMedCrossRef
193.
Raine AE. The rising tide of diabetic nephropathy: the warning before the flood? Nephrol Dial Transplant 1995; 10(4): 460–1PubMedCrossRef
194.
Andersen AR, Christiansen JS, Andersen JK, et al. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983 Dec; 25(6): 496–501PubMedCrossRef
195.
Sasso FC, De Nicola L, Carbonara O, et al. Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care 2006 Mar; 29(3): 498–503PubMedCrossRef
196.
Hasslacher C, Kempe HP, Bostedt-Kiesel A. ACE inhibitors and diabetic nephropathy: clinical and experimental findings. Clin Investig 1993; 71 (5 Suppl.): S20–4PubMed
197.
Ebihara I, Nakamura T, Shimada N, et al. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1998 Oct; 32(4): 544–50PubMedCrossRef
198.
Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996 Feb 12; 156(3): 286–9PubMedCrossRef
199.
Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997 Oct; 20(10): 1576–81PubMedCrossRef
200.
Gill GV, Hardy KJ, Patrick AW, et al. Random blood glucose estimation in type 2 diabetes: does it reflect overall glycaemic control? Diabet Med 1994 Aug–Sep; 11(7): 705–8PubMedCrossRef
201.
Meeme A, Kasozi H. Effect of glycaemic control on glomerular filtration rate in diabetes mellitus patients. Afr Health Sci 2009 Aug 1; 9 Suppl. 1: S23–6PubMedPubMedCentral
202.
Maurer AC. The therapy of diabetes. Am Sci 1979 Jul–Aug; 67(4): 422–31PubMed
203.
Madacsy L, Bokor M, Matusovits L. Penicillin clearance in diabetic children. Acta Paediatr Acad Sci Hung 1975; 16(2): 139–42PubMed
204.
Garcia G, de Vidal EL, Trujillo H. Serum levels and urinary concentrations of kanamicin, bekanamicin and amikacin (BB-K8) in diabetic children and a control group. J Int Med Res 1977; 5(5): 322–9PubMedCrossRef
205.
Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004 Dec 1; 292(21): 2585–90PubMedCrossRef
206.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21–27; 364(9435): 685–96PubMedCrossRef
207.
Skottheim IB, Gedde-Dahl A, Hejazifar S, et al. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci 2008 Apr 23; 33(4–5): 317–25PubMedCrossRef
208.
Berlin I, Grimaldi A, Bosquet F, et al. Decreased beta-adrenergic sensitivity in insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1986 Jul; 63(1): 262–5PubMedCrossRef
209.
210.
Berlin I, Grimaldi A, Landault C, et al. Lack of hypoglycemic symptoms and decreased beta-adrenergic sensitivity in insulin-dependent diabetic patients. J Clin Endocrinol Metab 1988 Feb; 66(2): 273–8PubMedCrossRef
211.
Berlin I, Grimaldi A, Payan C, et al. Hypoglycemic symptoms and decreased beta-adrenergic sensitivity in insulin-dependent diabetic patients. Diabetes Care 1987 Nov–Dec; 10(6): 742–7PubMedCrossRef
212.
Lynch C, Exton J. Alterations in G-protein-mediated cell signaling in diabetes mellitus. In: Milligan G, Wakelam M, editors. G-proteins: signal transduction and disease. London: Academic Press Limited, 1992: 87–108
213.
Terada M, Yasuda H, Kashawagi A, et al. Sympathetic nerve dysfunction and increased heart rate response to epinephrine in diabetic patients. Amsterdam: Elsevier Science Publishers, 1987
214.
Packer M, Lee WH, Medina N, et al. Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. Am J Med 1987 Jun; 82(6): 1119–26PubMedCrossRef
215.
Self TH, Hood J, Miller ST. Diabetes mellitus and the hypoprothrombinemic response to warfarin [letter]. JAMA 1978 May 26; 239(21): 2239PubMedCrossRef
216.
Lansang MC, Ma L, Schold JD, et al. The relationship between diabetes and infectious hospitalizations in renal transplant recipients. Diabetes Care 2006 Jul; 29(7): 1659–60PubMedCrossRef
217.
218.
Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003 Feb; 3(2): 178–85PubMedCrossRef
219.
Ye X, Kuo HT, Sampaio MS, et al. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clin Transplant 2011; 25(6): 885–91PubMedCrossRef
220.
Mendonza AE, Gohh RY, Akhlaghi F. Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. Clin Pharmacokinet 2008; 47(11): 733–42PubMedCrossRef
221.
Akhlaghi F, Dostalek M, Falck P, et al. The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus. Ther Drug Monit 2012; 34(1): 38–45PubMedCrossRef
222.
Mendonza AE, Zahir H, Gohh RY, et al. Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2007 Aug; 29(4): 391–8PubMedCrossRef
223.
van Duijnhoven E, Christiaans M, Undre N, et al. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. Transplant Proc 1998 Jun; 30(4): 1268–70PubMedCrossRef
224.
Akhlaghi F, Patel CG, Zuniga XP, et al. Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit 2006 Feb; 28(1): 95–101PubMedCrossRef
225.
van Hest RM, Mathot RA, Vulto AG, et al. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2004 Dec; 26(6): 620–5PubMedCrossRef
226.
Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003 Dec; 3(12): 1581–6PubMedCrossRef
227.
Akhlaghi F, Dostalek M, Mendonza AE, et al. Reduced levels of biomarkers of immunosuppressive activity in diabetic kidney transplant recipients [poster no. P204]. International Association of Therapeutic Drug Monitoring and Clinical Toxicology; 2011 Oct 2–6; Stuttgart, Germany
228.
Akhlaghi F, Chitnis SD, Ionita I, et al. Impact of diabetes mellitus on metabolism of immunosuppressive agents: cyclosporin, tacrolimus and prednisone [poster no. P201]. International Association of Therapeutic Drug Monitoring and Clinical Toxicology; 2011 Oct 2–6; Stuttgart, Germany
229.
Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 2001 Jun; 24(6): 1044–9PubMedCrossRef
230.
Alba-Loureiro TC, Munhoz CD, Martins JO, et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res 2007 Aug; 40(8): 1037–44PubMedCrossRef
231.
Jolin T, Tarin MJ, Garcia MD. Induction of goitre by PTU or KCIO4 in male and female rats: effect of gonadectomy. Acta Endocrinol (Copenh) 1973 Sep; 74(1): 88–104
232.
Garcia-Leme J, Bohm GM, Migliorini RH, et al. Possible participation of insulin in the control of vascular permeability. Eur J Pharmacol 1974 Dec; 29(2): 298–306PubMedCrossRef
233.
Llorach MA, Bohm GM, Leme JG. Decreased vascular reactions to permeability factors in experimental diabetes. Br J Exp Pathol 1976 Dec; 57(6): 747–54PubMedPubMedCentral
234.
Fortes ZB, Garcia Leme J, Scivoletto R. Vascular reactivity in diabetes mellitus: role of the endothelial cell. Br J Pharmacol 1983 Jul; 79(3): 771–81PubMedPubMedCentralCrossRef
235.
Fortes ZB, Garcia Leme J, Scivoletto R. Vascular reactivity in diabetes mellitus: possible role of insulin on the endothelial cell. Br J Pharmacol 1984 Nov; 83(3): 635–43PubMedPubMedCentralCrossRef
236.
Cavalher-Machado SC, de Lima WT, Damazo AS, et al. Down-regulation of mast cell activation and airway reactivity in diabetic rats: role of insulin. Eur Respir J 2004 Oct; 24(4): 552–8PubMedCrossRef
237.
Sannomiya P, Pereira MA, Garcia-Leme J. Inhibition of leukocyte chemotaxis by serum factor in diabetes mellitus: selective depression of cell responses mediated by complement-derived chemoattractants. Agents Actions 1990 Jun; 30(3–4): 369–76PubMedCrossRef
238.
Sannomiya P, Oliveira MA, Fortes ZB. Aminoguanidine and the prevention of leukocyte dysfunction in diabetes mellitus: a direct vital microscopic study. Br J Pharmacol 1997 Nov; 122(5): 894–8PubMedPubMedCentralCrossRef
239.
Fortes ZB, Farsky SP, Oliveira MA, et al. Direct vital microscopic study of defective leukocyte-endothelial interaction in diabetes mellitus. Diabetes 1991 Oct; 40(10): 1267–73PubMedCrossRef
240.
Cruz JW, Oliveira MA, Hohman TC, et al. Influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol 2000 Mar 10; 391(1–2): 163–74PubMedCrossRef
241.
Zanardo RC, Cruz JW, Martinez LL, et al. Probucol restores the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol 2003 Oct 8; 478(2–3): 211–9PubMedCrossRef
242.
Anjos-Valotta EA, Martins JO, Oliveira MA, et al. Inhibition of tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 expression in diabetic rats: role of insulin. Inflamm Res 2006 Jan; 55(1): 16–22PubMedCrossRef
243.
Moriguchi P, Sannomiya P, Lara PF, et al. Lymphatic system changes in diabetes mellitus: role of insulin and hyperglycemia. Diabetes Metab Res Rev 2005; 21(2): 150–7PubMedCrossRef
244.
Boichot E, Sannomiya P, Escofier N, et al. Endotoxin-induced acute lung injury in rats: role of insulin. Pulm Pharmacol Ther 1999; 12(5): 285–90PubMedCrossRef
245.
Shaw LM, Figurski M, Milone MC, et al. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol 2007 Sep; 2(5): 1062–72PubMedCrossRef
246.
Patel CG, Richman K, Yang D, et al. Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. Ther Drug Monit 2007 Dec; 29(6): 735–42PubMedPubMedCentralCrossRef
247.
Jain J, Almquist SJ, Ford PJ, et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol 2004 Feb 15; 67(4): 767–76PubMedCrossRef
248.
Fulton B, Markham A. Mycophenolate mofetil: a review of its pharmaco-dynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996 Feb; 51(2): 278–98PubMedCrossRef
249.
Abbott KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001 Dec; 3(4): 203–11PubMedCrossRef
250.
Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients: an analysis of USRDS data. Am J Transplant 2007 Mar; 7(3): 653–61PubMedCrossRef
251.
Redman DR, Prescott LF. Failure of induction of liver microsomal enzymes by tolbutamide in maturity-onset diabetics. Diabetes 1973 Mar; 22(3): 210–1PubMedCrossRef
252.
Sambol NC, Chiang J, O’Conner M, et al. Pharmacokinetics and pharmaco-dynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996 Nov; 36(11): 1012–21PubMedCrossRef
253.
Plosker GL, Figgitt DP. Repaglinide: a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics 2004; 22(6): 389–411PubMedCrossRef
Metadata
Title
Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs
Authors
Miroslav Dostalek
Fatemeh Akhlaghi
Dr Martina Puzanovova
Publication date
01-08-2012
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 8/2012
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/BF03261926

Other articles of this Issue 8/2012

Clinical Pharmacokinetics 8/2012 Go to the issue

Review Article

Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

Review Article

Fundamentals of Population Pharmacokinetic Modelling

Original Research Article

Propofol Clearance in Morbidly Obese Children and Adolescents

Original Research Article

Prediction of Clearance and Volume of Distribution in the Obese from Normal Weight Subjects